*********Good Lord I bet the NIH would think I should be dead....I take
16,000 to 24,000 mgs of BioEnergyC DAILY....my dogs also get the
BioEnergyC....
Linda
Everything you think you know about vitamin C is probably more than 50%
wrong and, if you relied on this official appearing document re vitamin C,
you would not use it. The attached document is from NIH so it gives you
all the negative but you must know all that too.
But I am providing you with the contrary opinion. You will be amazed at
how the right hand of the government does not know what the left hand is
doing! FDA has approved vitamin C for treating one type of cancer! That opens
the door to great speculation and further research about non-toxic cancer
therapies and I am excited to incorporate into this program the power of
PEMF, which makes each cell ALKALINE and restores transmembrane potential. So
I believe I have two or more non-toxic approaches that need to be looked at
concurrently and incorporated with my FIGHT program for long term success.
Using IV VIT C with my FIGHT program and PEMF ( Pulsed Electromagnetic
Field Therapy ) you will see and feel results with PEMF on top of my FIGHT
program, I am clearly getting younger!
There are other ways to enhance the effectiveness of high dose IV Vitamin
C in treating cancer and using it alone I do not find that IV VIT C is very
often curative but it almost always helps and buys time for other
therapies to be instituted.
Remember we all need to improve outcomes, as our patients pay cash. We
are not endowed by Government funds like our brethren using their
chemo/radiation. They are generally covered and just bill the system and are ok no
matter what the outcome. We are NOT OK unless we turn out superior
results and have data that shows we can beat mainstream outcomes hands down.
This NIH authoritative appearing well– referenced document would make
anyone think oral low dose (2000 mg and under) Vitamin C is dangerous and
causes cancer and heart disease. It appears to be fully referenced up to date
through November 2009 yet it is missing an important point; somehow IV
vitamin C WITH K-3 is now FDA approved for treating bladder cancer!! After all if
anyone knew that vitamin C could be FDA approved for one cancer then some
doctors would have some interest in trying it in other cancers just like
the oncologists do everyday.
How can I and many of our colleagues be successfully using oral and IV
vitamin C to keep Cancer patients alive far longer than their oncologists
predict and still be considered by mainstream oncologists to be so wrong? They
tell their patients to never use vitamin C!
This report even has recommendations about not exceeding what they have
established now, as their safe upper limit of oral vitamin C at 2000 mg MAX.
Yet it is hard for them to ignore entirely what we are doing with cancer so
they throw in some words to try to sound plausible with their otherwise
very negative review of vitamin C. This is BURIED in the attached report but
of course they have their numbers about what the maximum serum levels
achievable with oral vitamin c vs. the high serum levels achievable with IV
Vitamin C. Those that are interested to get to the bottom of this mystery will
find that vitamin c deserves your serious attention, IV and ORAL because
there is always the rest of the story.
This is just one paragraph from many articles you may want to review once
you read my comments: 'The bottom line is: Apatone selectively targets and
kills tumor cells using non-toxic biochemistry that protects surrounding
healthy tissue." Licensed in 2004 to IC-MedTech, Inc., a California-based
biotechnology company, the first clinical trial began in 2005 to evaluate the
drug in prostate cancer patients. The clinical studies, which were
conducted at Summa Health System in Akron, Ohio and with Dr. Ananias Diokno at
William Beaumont Hospital in Royal Oak, Mich., examined the safety and
effectiveness in 17 end-stage prostate cancer patients for 12 weeks. These patients
took Apatone orally each day. The trials were supported by the Beaumont
Foundation, Summa Health System and IC-MedTech.
Yet this is the best that the NIH report can offer the informed patients
and physicians trying to help cancer patients. They admit there could be
some discrepancy in the research but clearly tell no one that vitamin C is
working when mixed with the correct form of vitamin K-3 (Apatone), which
increases its oxidative capacity.
Remember this work using vitamin C for cancer goes back several years
now and it consists IV vitamin C with the correct form of vitamin K, which
unfortunately it appears that most physicians have never found the
correct form since there appears to be as many as 6 molecules being sold as
vitamin K-3 and some are toxic. Yet in the lecture I will deliver for The
Oxidative Training Workshop during IMOSAIC on April 7th at the Minneapolis
conference, sponsored by ACAM, AHIMA, AAEM and ICIM, I will educate you about
how easily you can kill the therapeutic effect when you are trying to master
oxidative therapies with something as simple as giving NAC or GLUTATHIONE
concurrently.
Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com
From: Wayne Harris
http://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/
NIH Office of Dietary Supplements
Dietary Supplement Fact Sheet:
Vitamin C
Introduction
Vitamin C, also known as L-ascorbic acid, is a water-soluble vitamin that
is naturally present in some foods, added to others, and available as a
dietary supplement. Humans, unlike most animals, are unable to synthesize
vitamin C endogenously, so it is an essential dietary component [1].
Vitamin C is required for the biosynthesis of collagen, L-carnitine, and
certain neurotransmitters; vitamin C is also involved in protein metabolism
[1,2]. Collagen is an essential component of connective tissue, which plays
a vital role in wound healing. Vitamin C is also an important
physiological antioxidant [3] and has been shown to regenerate other antioxidants
within the body, including alpha-tocopherol (vitamin E) [4]. Ongoing research is
examining whether vitamin C, by limiting the damaging effects of free
radicals through its antioxidant activity, might help prevent or delay the
development of certain cancers, cardiovascular disease, and other diseases in
which oxidative stress plays a causal role. In addition to its biosynthetic
and antioxidant functions, vitamin C plays an important role in immune
function [4] and improves the absorption of nonheme iron [5], the form of iron
present in plant-based foods. Insufficient vitamin C intake causes scurvy,
which is characterized by fatigue or lassitude, widespread connective tissue
weakness, and capillary fragility [1,2,4,6-9].
The intestinal absorption of vitamin C is regulated by at least one
specific dose-dependent, active transporter [4]. Cells accumulate vitamin C via a
second specific transport protein. In vitro studies have found that
oxidized vitamin C, or dehydroascorbic acid, enters cells via some facilitated
glucose transporters and is then reduced internally to ascorbic acid. The
physiologic importance of dehydroascorbic acid uptake and its contribution to
overall vitamin C economy is unknown.
Oral vitamin C produces tissue and plasma concentrations that the body
tightly controls. Approximately 70%–90% of vitamin C is absorbed at moderate
intakes of 30–180 mg/day. However, at doses above 1 g/day, absorption falls
to less than 50% and absorbed, unmetabolized ascorbic acid is excreted in
the urine [4]. Results from pharmacokinetic studies indicate that oral doses
of 1.25 g/day ascorbic acid produce mean peak plasma vitamin C
concentrations of 135 micromol/L, which are about two times higher than those produced
by consuming 200–300 mg/day ascorbic acid from vitamin C-rich foods [10].
Pharmacokinetic modeling predicts that even doses as high as 3 g ascorbic
acid taken every 4 hours would produce peak plasma concentrations of only
220 micromol/L [10].
The total body content of vitamin C ranges from 300 mg (at near scurvy) to
about 2 g [4]. High levels of vitamin C (millimolar concentrations) are
maintained in cells and tissues, and are highest in leukocytes (white blood
cells), eyes, adrenal glands, pituitary gland, and brain. Relatively low
levels of vitamin C (micromolar concentrations) are found in extracellular
fluids, such as plasma, red blood cells, and saliva [4].
Recommended Intakes
Intake recommendations for vitamin C and other nutrients are provided in
the Dietary Reference Intakes (DRIs) developed by the Food and Nutrition
Board (FNB) at the Institute of Medicine (IOM) of the National Academies
(formerly National Academy of Sciences) [8]. DRI is the general term for a set
of reference values used for planning and assessing nutrient intakes of
healthy people. These values, which vary by age and gender [8], include:
• Recommended Dietary Allowance (RDA): average daily level of intake
sufficient to meet the nutrient requirements of nearly all (97%–98%) healthy
individuals.
• Adequate Intake (AI): established when evidence is insufficient
to develop an RDA and is set at a level assumed to ensure nutritional
adequacy.
• Tolerable Upper Intake Level (UL): maximum daily intake unlikely to
cause adverse health effects [8].
Table 1 lists the current RDAs for vitamin C [8]. The RDAs for vitamin C
are based on its known physiological and antioxidant functions in white
blood cells and are much higher than the amount required for protection from
deficiency [4,8,11]. For infants from birth to 12 months, the FNB established
an AI for vitamin C that is equivalent to the mean intake of vitamin C in
healthy, breastfed infants.
Dietary supplements
Supplements typically contain vitamin C in the form of ascorbic acid,
which has equivalent bioavailability to that of naturally occurring ascorbic
acid in foods, such as orange juice and broccoli [13-15]. Other forms of
vitamin C supplements include sodium ascorbate; calcium ascorbate; other
mineral ascorbates; ascorbic acid with bioflavonoids; and combination products,
such as Ester-C®, which contains calcium ascorbate, dehydroascorbate,
calcium threonate, xylonate and lyxonate [16].
A few studies in humans have examined whether bioavailability differs
among the various forms of vitamin C. In one study, Ester-C® and ascorbic acid
produced the same vitamin C plasma concentrations, but Ester-C® produced
significantly higher vitamin C concentrations in leukocytes 24 hours after
ingestion [17]. Another study found no differences in plasma vitamin C levels
or urinary excretion of vitamin C among three different vitamin C sources:
ascorbic acid, Ester-C®, and ascorbic acid with bioflavonoids [16]. These
findings, coupled with the relatively low cost of ascorbic acid, led the
authors to conclude that simple ascorbic acid is the preferred source of
supplemental vitamin C [16].
Vitamin C and Health
Due to its function as an antioxidant and its role in immune function,
vitamin C has been promoted as a means to help prevent and/or treat numerous
health conditions. This section focuses on four diseases and disorders in
which vitamin C might play a role: cancer (including prevention and
treatment), cardiovascular disease, age-related macular degeneration (AMD) and
cataracts, and the common cold.
Cancer prevention
Epidemiologic evidence suggests that higher consumption of fruits and
vegetables is associated with lower risk of most types of cancer, perhaps, in
part, due to their high vitamin C content [1,2]. Vitamin C can limit the
formation of carcinogens, such as nitrosamines [2,28], in vivo; modulate immune
response [2,4]; and, through its antioxidant function, possibly attenuate
oxidative damage that can lead to cancer [1].
Most case-control studies have found an inverse association between
dietary vitamin C intake and cancers of the lung, breast, colon or rectum,
stomach, oral cavity, larynx or pharynx, and esophagus [2,4]. Plasma
concentrations of vitamin C are also lower in people with cancer than controls [2].
However, evidence from prospective cohort studies is inconsistent,
possibly due to varying intakes of vitamin C among studies. In a cohort of 82,234
women aged 33–60 years from the Nurses' Health Study, consumption of an
average of 205 mg/day of vitamin C from food (highest quintile of intake)
compared with an average of 70 mg/day (lowest quintile of intake) was
associated with a 63% lower risk of breast cancer among premenopausal women with a
family history of breast cancer [29]. Conversely, Kushi and colleagues did
not observe a significantly lower risk of breast cancer among postmenopausal
women consuming at least 198 mg/day (highest quintile of intake) of
vitamin C from food compared with those consuming less than 87 mg/day (lowest
quintile of intake) [30]. A review by Carr and Frei concluded that in the
majority of prospective cohort studies not reporting a significantly lower
cancer risk, most participants had relatively high vitamin C intakes, with
intakes higher than 86 mg/day in the lowest quintiles [2]. Studies reporting
significantly lower cancer risk found these associations in individuals with
vitamin C intakes of at least 80–110 mg/day, a range associated with close
to vitamin C tissue saturation [2,21,31].
Evidence from most randomized clinical trials suggests that vitamin C
supplementation, usually in combination with other micronutrients, does not
affect cancer risk. In the Supplémentation en Vitamines et Minéraux
Antioxydants (SU.VI.MAX) study, a randomized, double-blind, placebo-controlled
clinical trial,13,017 healthy French adults received antioxidant supplementation
with 120 mg ascorbic acid, 30 mg vitamin E, 6 mg beta-carotene, 100 mcg
selenium, and 20 mg zinc, or placebo [32]. After a median follow-up time of
7.5 years, antioxidant supplementation lowered total cancer incidence in men,
but not in women. In addition, baseline antioxidant status was related to
cancer risk in men, but not in women [33]. Supplements of 500 mg/day
vitamin C plus 400 IU vitamin E every other day for a mean follow-up period of 8
years failed to reduce the risk of prostate or total cancer compared with
placebo in middle-aged and older men participating in the Physicians' Health
Study II [34]. Similar findings were reported in women participating in
the Women's Antioxidant Cardiovascular Study [35]. Compared with placebo,
supplementation with vitamin C (500 mg/day) for an average of 9.4 years had no
significant effect on total cancer incidence or cancer mortality. In a
large intervention trial conducted in Linxian, China, daily supplements of
vitamin C (120 mg) plus molybdenum (30 mcg) for 5–6 years did not significantly
affect the risk of developing esophageal or gastric cancer [36]. Moreover,
during 10 years of follow-up, this supplementation regimen failed to
significantly affect total morbidity or mortality from esophageal, gastric, or
other cancers [37]. A 2008 review of vitamin C and other antioxidant
supplements for the prevention of gastrointestinal cancers found no convincing
evidence that vitamin C (or beta-carotene, vitamin A, or vitamin E) prevents
gastrointestinal cancers [38]. A similar review by Coulter and colleagues
found that vitamin C supplementation, in combination with vitamin E, had no
significant effect on death risk due to cancer in healthy individuals [39].
At this time, the evidence is inconsistent on whether dietary vitamin C
intake affects cancer risk. Results from most clinical trials suggest that
modest vitamin C supplementation alone or with other nutrients offers no
benefit in the prevention of cancer.
A substantial limitation in interpreting many of these studies is that
investigators did not measure vitamin C concentrations before or after
supplementation. Plasma and tissue concentrations of vitamin C are tightly
controlled in humans. At daily intakes of 100 mg or higher, cells appear to be
saturated and at intakes of at least 200 mg, plasma concentrations increase
only marginally [2,10,21,30,36]. If subjects' vitamin C levels were already
close to saturation at study entry, supplementation would be expected to
have made little or no difference on measured outcomes [21,22,40,41].
Cancer treatment
During the 1970s, studies by Cameron, Campbell, and Pauling suggested that
high-dose vitamin C has beneficial effects on quality of life and survival
time in patients with terminal cancer [42,43]. However, some subsequent
studies—including a randomized, double-blind, placebo-controlled clinical
trial by Moertel and colleagues at the Mayo Clinic [44]—did not support these
findings. In the Moertel study, patients with advanced colorectal cancer who
received 10 g/day vitamin C fared no better than those receiving a
placebo. The authors of a 2003 review assessing the effects of vitamin C in
patients with advanced cancer concluded that vitamin C confers no significant
mortality benefit [39].
Emerging research suggests that the route of vitamin C administration
(intravenous vs. oral) could explain the conflicting findings [1,45,46]. Most
intervention trials, including the one conducted by Moertel and colleagues,
used only oral administration, whereas Cameron and colleagues used a
combination of oral and intravenous (IV) administration. Oral administration of
vitamin C, even of very large doses, can raise plasma vitamin C
concentrations to a maximum of only 220 micromol/L, whereas IV administration can
produce plasma concentrations as high as 26,000 micromol/L [46,47].
Concentrations of this magnitude are selectively cytotoxic to tumor cells in vitro
[1,66]. Research in mice suggests that pharmacologic doses of IV vitamin C might
show promise in treating otherwise difficult-to-treat tumors [48]. A high
concentration of vitamin C may act as a pro-oxidant and generate hydrogen
peroxide that has selective toxicity toward cancer cells [48-50]. Based on
these findings and a few case reports of patients with advanced cancers who
had remarkably long survival times following administration of high-dose IV
vitamin C, some researchers support reassessment of the use of high-dose
IV vitamin C as a drug to treat cancer [3,46,48,51].
As discussed below, it is uncertain whether supplemental vitamin C and
other antioxidants might interact with chemotherapy and/or radiation [52].
Therefore, individuals undergoing these procedures should consult with their
oncologist prior to taking vitamin C or other antioxidant supplements,
especially in high doses [53].
Chemotherapy and radiation
The safety and efficacy of the use of vitamin C and other antioxidants
during cancer treatment is controversial [52,88,89]. Some data indicate that
antioxidants might protect tumor cells from the action of radiation therapy
and chemotherapeutic agents, such as cyclophosphamide, chlorambucil,
carmustine, busulfan, thiotepa, and doxorubicin [53,88,90,91]. At least some of
these data have been criticized because of poor study design [51]. Other
data suggest that antioxidants might protect normal tissues from chemotherapy-
and radiation-induced damage [88,90] and/or enhance the effectiveness of
conventional cancer treatment [92]. However, due to the physiologically
tight control of vitamin C, it is unclear whether oral vitamin C supplements
could alter vitamin C concentrations enough to produce the suggested effects.
Individuals undergoing chemotherapy or radiation should consult with their
oncologist prior to taking vitamin C or other antioxidant supplements,
especially in high doses [53].
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)
Vitamin C, in combination with other antioxidants, may attenuate the
increase in high-density lipoprotein levels resulting from combination niacin–
simvastatin (Zocor®) therapy [93,94]. It is not known whether this
interaction occurs with other lipid-altering regimens [53]. Health care providers
should monitor lipid levels in individuals taking both statins and antioxidant
supplements [53].
References, charts and more information are available through link
provided above.
[Non-text portions of this message have been removed]
Peacefulmind.com Sponsors Alternative Answers-
HEALING NATURALLY- Learn preventative and curative measure to take for many ailments at:
http://www.peacefulmind.com/ailments.htm
____________________________________________
-To INVITE A FRIEND to our healing community, copy and paste this address in an email to them:
http://health.groups.yahoo.com/group/AlternativeAnswers/subs_invite
___________________________________________
To ADD A LINK, RESOURCE, OR WEBSITE to Alternative Answers please Go to:
http://health.groups.yahoo.com/group/AlternativeAnswers/links
_____________________________________________
Community email addresses:
Post message: AlternativeAnswers@yahoogroups.com
Subscribe: AlternativeAnswers-subscribe@yahoogroups.com
Unsubscribe: AlternativeAnswers-unsubscribe@yahoogroups.com
List owner: AlternativeAnswers-owner@yahoogroups.com
_________________________________________
Shortcut URL to this page:
http://health.groups.yahoo.com/group/AlternativeAnswers
No comments:
Post a Comment